Oral Amiodarone for Acute Cardioversion of Atrial Fibrillation Study

Summary

The investigators will seek to determine the safety and efficacy of high-dose amiodarone (2000mg), given as a single uniform oral dose, for the treatment of acute atrial fibrillation in both a hospital inpatient and ambulatory outpatient setting. The investigators will conduct a placebo-controlled randomized trial, with outcome ascertainment at 48h.

Timeline

Start

2022-02-03

Primary completion

2026-01-20

Completion

2026-01-20

Drugs

Indications